Stock Events

Stock Events

Atossa Therapeutics 

€4.56
315
+€0+0% Wednesday 10:03

Statistics

Day High
4.56
Day Low
4.56
52W High
15.24
52W Low
4.56
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

18MayExpected
Q4 2025
Next
-1.03
-0.97
-0.91
-0.84
Expected EPS
-0.843975
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow YAG.MU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap149.77B
Pfizer is involved in developing treatments in various therapeutic areas, including those Atossa is targeting, making them direct competitors in the pharmaceutical space.
Merck
MRK
Mkt Cap277.02B
Merck operates in similar therapeutic areas as Atossa, including breast cancer treatments, positioning them as competitors.
Novartis
NVS
Mkt Cap279.67B
Novartis competes with Atossa in the oncology sector, particularly in developing treatments for breast cancer.
Gilead Sciences
GILD
Mkt Cap163.4B
Gilead Sciences focuses on innovative therapies, including for cancer, directly competing with Atossa's therapeutic development efforts.
AMGEN
AMGN
Mkt Cap178B
Amgen's focus on biologics and treatments for serious illnesses places them in competition with Atossa, especially in cancer therapy.
Abbvie
ABBV
Mkt Cap365.43B
AbbVie's work in oncology and focus on innovative treatments make them a competitor to Atossa in the pharmaceutical and biotech industry.
Astrazeneca
AZN
Mkt Cap286.4B
AstraZeneca's extensive research in oncology, including breast cancer, positions them as a competitor to Atossa.
Bristol-Myers Squibb
BMY
Mkt Cap118.87B
Bristol Myers Squibb's involvement in cancer research and development of oncology treatments competes with Atossa's focus areas.
Lilly(Eli) &
LLY
Mkt Cap862.01B
Eli Lilly's commitment to cancer research, including breast cancer, makes them a direct competitor to Atossa in the pharmaceutical industry.

About

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201, an inhalation therapy to improve lung function in severely ill and hospitalized COVID-19 patients; AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-19; and immunotherapy/chimeric antigen receptor therapy programs for the treatment of breast cancer. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.
Show more...
CEO
ISIN
US04962H7044

Listings

STU
DE
YAG.STU
MU
DE
YAG.MU
BOATS
BOATS
ATOS.BOATS
MX
MX
ATOS.MX

0 Comments

Share your thoughts

FAQ

What is Atossa Therapeutics stock price today?▼
The current price of YAG.MU is €4.56 EUR — it has increased by +0% in the past 24 hours. Watch Atossa Therapeutics stock price performance more closely on the chart.
What is Atossa Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Atossa Therapeutics stocks are traded under the ticker YAG.MU.
Is Atossa Therapeutics stock price growing?▼
YAG.MU stock has fallen by -41.31% compared to the previous week, the month change is a -41.31% fall, over the last year Atossa Therapeutics has showed a -58.86% decrease.
When is the next Atossa Therapeutics earnings date?▼
Atossa Therapeutics is going to release the next earnings report on May 18, 2026.
What were Atossa Therapeutics earnings last quarter?▼
YAG.MU earnings for the last quarter are -1.03 EUR per share, whereas the estimation was -0.98 EUR resulting in a -4.62% surprise. The estimated earnings for the next quarter are N/A EUR per share.
In which sector is Atossa Therapeutics located?▼
Atossa Therapeutics operates in the Other sector.
When did Atossa Therapeutics complete a stock split?▼
The last stock split for Atossa Therapeutics was on February 02, 2026 with a ratio of 1:15.